COVID-19 therapeutics to include a “conditional recommendation" on Merck & Co's Covid drug Molnupiravir, a new antiviral medicine.
Under this conditional approval, Merck's Covid-19 antiviral pill was approved for patients who are in the early stages of the disease.WHO has updated its living guidelines on #COVID19 therapeutics to include a conditional recommendation on molnupiravir, a new antiviral medicine.https://t.co/ZRygSEAbzC As per the global health body, Molnupiravir should only be “provided to non-severe COVID-19 patients" with the highest risk of hospitalisation.
Patients who come in this category are those who have not received a COVID-19 vaccination, older people, people with immunodeficiencies and people living with chronic diseases like diabetes.
As this is a new drug, the WHO has recommended active monitoring for drug safety, along with other strategies to mitigate potential harms. “Children, pregnant and breastfeeding women should not be given the drug.
Read more on livemint.com